Seaport Therapeutics, Inc. (SPTX)
Seaport Therapeutics will go public soon. The estimated IPO date is May 1, 2026.
IPO Price Range
$16.00 - $18.00
Shares Offered
11,800,000
Deal Size
$200.60M
Seaport Therapeutics Statistics
Total Valuation
SPTX has a market cap or net worth of $861.35 million. The enterprise value is $650.45 million.
| Market Cap | 861.35M |
| Enterprise Value | 650.45M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SPTX has 50.67 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 50.67M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 7.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.07% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SPTX has paid $773,000 in taxes.
| Income Tax | 773,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -87.29M |
| Pretax Income | -74.11M |
| Net Income | -74.88M |
| EBITDA | -87.54M |
| EBIT | -85.51M |
| Earnings Per Share (EPS) | -$1.48 |
Balance Sheet
The company has $215.98 million in cash and $5.08 million in debt, with a net cash position of $210.90 million or $4.16 per share.
| Cash & Cash Equivalents | 215.98M |
| Total Debt | 5.08M |
| Net Cash | 210.90M |
| Net Cash Per Share | $4.16 |
| Equity (Book Value) | -92.55M |
| Book Value Per Share | -1.83 |
| Working Capital | 210.45M |
Cash Flow
In the last 12 months, operating cash flow was -$77.94 million and capital expenditures -$356,000, giving a free cash flow of -$78.30 million.
| Operating Cash Flow | -77.94M |
| Capital Expenditures | -356,000 |
| Depreciation & Amortization | -2.03M |
| Net Borrowing | n/a |
| Free Cash Flow | -78.30M |
| FCF Per Share | -$1.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -8.69% |
| FCF Yield | -9.09% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |